ArticleOPEN ACCESS

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

Health and Quality of Life Outcomes
DOI: 10.1186/s12955-017-0788-4
0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).

Author supplied keywords

Cite

CITATION STYLE

APA

Breccia, M., Baccarani, M., Rosti, G., Cottone, F., Cannella, L., Guilhot, F., … Efficace, F. (2017, October 18). Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. Health and Quality of Life Outcomes. BioMed Central. https://doi.org/10.1186/s12955-017-0788-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free